VXRT:OTCMKTS
Vaxart Inc
0,77 US$
0,00%
(0,00) 1D
1. 5., 16:00:00 GMT-4 · USD
search
Všechny symboly
1D
5D
1M
6M
YTD
1R
5R
MAX
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro VXRT…
Otevřít
0,77 US$
Max.
0,79 US$
Min.
0,75 US$
Trž. kap.
185,29 mil.
Prům. obj.
458,71 tis.
Objem
781,95 tis.
Ukazatel P/E
10,86
52týd. max.
0,84 US$
52týd. min.
0,26 US$
EPS
0,07 US$
Beta
1,31
Akcie v oběhu
241,41 mil.
Počet zaměstnanců
65
Zpravodajské články
Ze zdrojů na internetu
Stock Titan
·
před 1 dnem
Vaxart (VXRT) director James B. Breitmeyer files initial Form 3 with no trades
Profil
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Informace o Vaxart Inc
Generální ředitel-
Zaměstnanci65
Založenobře 2004
ÚstředíSouth San Francisco, Kalifornie, Spojené státy americké
Odvětví-
Webvaxart.com
Obsah od AI může obsahovat chyby. Další informace